Call Us
1-888-INFO-FDA
(1-888-463-6332) or
(301) 827-4570
This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.
Sildenafil citrate (marketed as VIAGRA and REVATIO), vardenafil hydrochloride (marketed as LEVITRA), and tadalafil (marketed as CIALIS): Sudden Hearing Loss
U.S. Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
5600 Fishers Lane, Rockville MD 20857-0001
Phone: 1-888-INFO-FDA (1-888-463-6332)
Renan A. Bonnel, PharmD, MPH
Senior Scientific Editor
Acknowledgments:
Office of Surveillance and Epidemiology, Office of New Drugs, and Office of Translational Sciences
We value your comments. Please let us know by reaching us at www.fda.gov/cder/comment.htm. All text in the Drug Safety Newsletter is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.